Cost of decentralized CAR T-cell production in an academic nonprofit setting
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC..
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy with high acquisition costs, and it has raised concerns about affordability and sustainability in many countries. Furthermore, the current centralized production paradigm for the T cells is less than satisfactory. Therefore, several countries are exploring alternative T-cell production modes. Our study is based on the T-cell production experience in a nonprofit setting in Germany. We first identified the work steps and main activities in the production process. Then we determined the fixed costs and variable costs. Main cost components included personnel and technician salaries, expenditure on equipment, a clean room, as well as production materials. All costs were calculated in 2018 euros and converted into U.S. dollars. For a clean room with one machine for closed and automated manufacturing installed, annual fixed costs summed up to approximately €438 098 ($584 131). The variable cost per production was roughly €34 798 ($46 397). At the maximum capacity of one machine, total cost per product would be close to €60 000 ($78 849). As shown in the scenario analysis, if three machines were to be installed in the clean room, per production cost could be as low as €45 000 (roughly $59905). If a cheaper alternative to lentivirus was used, per production total cost could be further reduced to approximately €33 000 (roughly $44309). Decentralized T-cell production might be a less costly and more efficient alternative to the current centralized production mode that requires a high acquisition cost.
| Errataetall: |
CommentIn: Int J Cancer. 2021 Jan 15;148(2):514-515. - PMID 32798335 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:147 |
|---|---|
| Enthalten in: |
International journal of cancer - 147(2020), 12 vom: 15. Dez., Seite 3438-3445 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ran, Tao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR-T cell therapy |
|---|
| Anmerkungen: |
Date Completed 16.04.2021 Date Revised 03.06.2021 published: Print-Electronic CommentIn: Int J Cancer. 2021 Jan 15;148(2):514-515. - PMID 32798335 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijc.33156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311150403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311150403 | ||
| 003 | DE-627 | ||
| 005 | 20231225141636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.33156 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311150403 | ||
| 035 | |a (NLM)32535920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ran, Tao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost of decentralized CAR T-cell production in an academic nonprofit setting |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2021 | ||
| 500 | |a Date Revised 03.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Int J Cancer. 2021 Jan 15;148(2):514-515. - PMID 32798335 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. | ||
| 520 | |a Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy with high acquisition costs, and it has raised concerns about affordability and sustainability in many countries. Furthermore, the current centralized production paradigm for the T cells is less than satisfactory. Therefore, several countries are exploring alternative T-cell production modes. Our study is based on the T-cell production experience in a nonprofit setting in Germany. We first identified the work steps and main activities in the production process. Then we determined the fixed costs and variable costs. Main cost components included personnel and technician salaries, expenditure on equipment, a clean room, as well as production materials. All costs were calculated in 2018 euros and converted into U.S. dollars. For a clean room with one machine for closed and automated manufacturing installed, annual fixed costs summed up to approximately €438 098 ($584 131). The variable cost per production was roughly €34 798 ($46 397). At the maximum capacity of one machine, total cost per product would be close to €60 000 ($78 849). As shown in the scenario analysis, if three machines were to be installed in the clean room, per production cost could be as low as €45 000 (roughly $59905). If a cheaper alternative to lentivirus was used, per production total cost could be further reduced to approximately €33 000 (roughly $44309). Decentralized T-cell production might be a less costly and more efficient alternative to the current centralized production mode that requires a high acquisition cost | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CAR-T cell therapy | |
| 650 | 4 | |a T-cell production | |
| 650 | 4 | |a costs | |
| 650 | 4 | |a good manufacturing practice | |
| 650 | 4 | |a price | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Eichmüller, Stefan B |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Schlander, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 147(2020), 12 vom: 15. Dez., Seite 3438-3445 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:147 |g year:2020 |g number:12 |g day:15 |g month:12 |g pages:3438-3445 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.33156 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 147 |j 2020 |e 12 |b 15 |c 12 |h 3438-3445 | ||